Chief Operating Officer · Dyne Therapeutics, Inc. (DYN)

Susanna High

A named executive officer of Dyne Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,045,442

Salary $497,888Stock awards $1,032,436

FY2022: $1,594,292

3rd of 4 named executive officers at Dyne Therapeutics by FY2023 total.

4 named officers on file for Dyne Therapeutics, FY2023

Susanna High’s pay file — $29

  • 4 fiscal years of pay, line by line
  • DYN’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Dyne Therapeutics’s whole pay program stands against its peers

  • Dyne Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on DYN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 5, 2024 (DEF 14A).

Free

Get Susanna High’s full pay file as a PDF — free

More than this page: up to 10 years of Susanna’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Susanna High compensation by year

Dyne Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Dyne Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023
Salary$167,778$425,000$467,500$497,888
Bonus$0$0$0$0
Stock awards$858,106$514,762$471,680$1,032,436
Option awards$2,646,267$528,933$467,116$255,220
Non-equity incentive$73,336$221,000$187,000$258,902
Pension and deferred compensation$0$0$0$0
All other$418$926$996$996
Total$3,745,905$1,690,621$1,594,292$2,045,442

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Dyne Therapeutics, Inc. DEF 14A filed April 5, 2024, accession 0000950170-24-042276, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Dyne Therapeutics, Inc. filed document, accession 0000950170-24-042276. Every figure is read from that document and cited to the page and table it appears in. Filed April 5, 2024.

$3.7M
$1.7M
$1.6M
$2.0M
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU94,893$1,262,077—
RSU44,000$585,200—
RSU30,239$402,179—
RSU17,952$238,762—
Option20,374—$5.54
Option36,182—$10.88
Option20,889—$19.00
Option41,342—$5.54
Option30,236—$13.12
Option51,750—$10.72

Per the Outstanding Equity Awards at Fiscal Year-End table in Dyne Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Dyne Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Josh BrummFormer President and Chief Executive Officer$5,974,491
Jonathan McNeillChief Business Officer$2,230,830
Susanna High · this pageChief Operating Officer$2,045,442
Oxana BeskrovnayaChief Innovation Officer; Former Chief Scientific Officer$1,997,845

The full Dyne Therapeutics compensation record

free company brief

This page is one person within Dyne Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Dyne Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Dyne Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Susanna High's compensation dossier · One-time report. No refunds.